Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 2/20 | 0.32 |
| ▸ | CTSB | P07858 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | HRH2 | P25021 | 2/20 | 0.31 |
| ▸ | HRH1 | P35367 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5567101 | 0.85 | CTSL (0.36) | CTSLCTSBCTSKHRH2HRH1 | |
| SCHEMBL5569273 | 0.72 | ACE (0.35) | CTSLCTSBCTSKHRH1 | |
| SCHEMBL27808912 | 0.69 | CA1 (0.47) | CTSLCTSBCTSKCA1CA2 | |
| SCHEMBL27808914 | 0.69 | CA1 (0.47) | CTSLCTSBCTSKCA1CA2 | |
| Hydrochloric Acid SCHEMBL5570438 | 0.69 | TTPA (0.32) | — | |
| SCHEMBL28414218 | 0.66 | CA1 (0.44) | CTSLCTSBCTSKCA1CA2 | |
| SCHEMBL10829199 | 0.64 | CTSL (0.45) | CTSL | |
| SCHEMBL28507462 | 0.63 | JAK3 (0.32) | CTSK | |
| SCHEMBL11602026 | 0.63 | CA1 (0.47) | CTSLCTSBCTSKCA1CA2 | |
| SCHEMBL7385030 | 0.62 | CTSK (0.44) | CTSLCTSBCTSKHRH2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7169805-B2 | Captopril derivatives | NICOX S.A. (FR) | 2007-01-30 | — | — | US | disclosed |
| EP-1626955-A1 | CAPTOPRIL DERIVATIVES | Nicox S.A. (FR) | 2006-02-22 | — | — | EP | disclosed |
| US-20040259808-A1 | Captopril derivatives | NICOX S.A. (FR) | 2004-12-23 | — | — | US | disclosed |
| WO-2004106300-A1 | CAPTOPRIL DERIVATIVES | NICOX S.A. (FR) | 2004-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259808-A1 | Captopril derivatives | REN, ACE, NPPA | CTSL 143/4885CTSB 114/4885CTSK 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.